Companies › Corium Innovations
2 active drug programs in 33 registered trials: 20 Phase 4, 6 Phase 2, 5 Phase 1, 2 Phase 3; Psychiatry, Gastroenterology, Genitourinary, Infectious disease; next expected readout May 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Estradiol Estrogen receptor alpha agonist | ESR1 | Phase 1 | Healthy Female Participants; Menopause; Perimenopause; Infertilities … | May 2027 |
| Selegiline Monoamine oxidase B inhibitor | MAOB | Phase 1 | Major Depressive Disorder (MDD) | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04043520 | Estradiol | Phase 4 | Menopause | Metabolic and endocrine | Aug 2024 |
| NCT04255160 | Estradiol | Phase 4 | Perimenopause | Genitourinary | Sep 2026 |
| NCT07452692 | Selegiline | Phase 1 | Major Depressive Disorder (MDD) | Psychiatry | Sep 2026 |
| NCT07851649 | Estradiol | Phase 1 | Healthy Female Participants | Genitourinary | Sep 2026 |
| NCT06896617 | Estradiol | Phase 4 | Infertilities | Genitourinary | Nov 2026 |
| NCT06798571 | Estradiol | Phase 4 | Menopause | Genitourinary | Dec 2026 |
| NCT06969326 | Estradiol | Phase 3 | Postoperative Bleeding | Psychiatry | Dec 2026 |
| NCT07083635 | Estradiol | Phase 2 | Menstruation Disturbances | Genitourinary | Dec 2026 |
| NCT05221021 | Estradiol | Phase 4 | Overactive Bladder Syndrome | Genitourinary | Dec 2026 |
| NCT05457972 | Estradiol | Phase 4 | Breastfeeding | Psychiatry | Dec 2026 |
| NCT05282277 | Estradiol | Phase 4 | Depression | Psychiatry | Dec 2026 |
| NCT07160504 | Estradiol | Phase 4 | Vagina Atrophy | Genitourinary | Dec 2026 |
| NCT06570460 | Estradiol | Phase 4 | Turner Syndrome | Metabolic and endocrine | Dec 2026 |
| NCT06570460 | Estradiol | Phase 4 | Turner Syndrome | Metabolic and endocrine | Dec 2026 |
| NCT06544473 | Estradiol | Phase 4 | Turner Syndrome | Metabolic and endocrine | Dec 2026 |
| NCT06544473 | Estradiol | Phase 4 | Turner Syndrome | Metabolic and endocrine | Dec 2026 |
| NCT04685148 | Estradiol | Phase 1 | Major Depressive Disorder | Psychiatry | Dec 2026 |
| NCT05723601 | Estradiol | Phase 4 | Recurrent Urinary Tract Infection | Infectious disease | Jan 2027 |
| NCT05723601 | Estradiol | Phase 4 | Recurrent Urinary Tract Infection | Infectious disease | Jan 2027 |
| NCT05716516 | Estradiol | Phase 2 | Metastatic Breast Cancer | Oncology | May 2027 |
| NCT07794150 | Estradiol | Phase 1 | Menopause | Genitourinary | May 2027 |
| NCT06353269 | Estradiol | Phase 4 | Recurrent Urinary Tract Infection | Infectious disease | Jun 2027 |
| NCT04833140 | Estradiol | Phase 3 | NASH - Nonalcoholic Steatohepatitis | Gastroenterology | Jul 2027 |
| NCT06856174 | Estradiol | Phase 4 | HIV Infection | Infectious disease | Sep 2027 |
| NCT07754630 | Estradiol | Phase 2 | Menopause | Genitourinary | Oct 2027 |
| NCT06686537 | Estradiol | Phase 2 | Infertility, Female | Metabolic and endocrine | Oct 2027 |
| NCT05900895 | Estradiol | Phase 1 | Metastatic Breast Cancer | Oncology | Dec 2027 |
| NCT06264882 | Estradiol | Phase 4 | Menopause | Metabolic and endocrine | May 2028 |
| NCT06610305 | Estradiol | Phase 4 | Major Depressive Disorder | Psychiatry | Jun 2028 |
| NCT02238808 | Estradiol | Phase 2 | Estrogen Receptor Positive Breast Cancer | Oncology | Jun 2028 |
| NCT07831499 | Estradiol | Phase 4 | Menopause | Genitourinary | Jul 2028 |
| NCT07831499 | Estradiol | Phase 4 | Menopause | Genitourinary | Jul 2028 |
| NCT03875378 | Estradiol | Phase 2 | Anorexia Nervosa | Psychiatry | Aug 2028 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.